ArticleToxics2025
Health Risks from Microplastics in Intravenous Infusions: Evidence from Italy, Spain, and Ecuador.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plastamination, Human Health, and Countries' Cultural Orientation: An Exploratory Study on Prevention Strategies and Organizational Policies and Practices.International journal of environmental research and public health · 2026Pooled it
- Micro- and Nanoplastics in Cardiovascular Toxicology: Human Tissue Detection, Clinical Phenotypes, and Adverse Outcome Signals.Cardiovascular toxicology · 2026Review
- Microplastics in Foods Intended for Health Purposes: From Dietary Supplements to Clinical Nutrition Products.Toxics · 2026Review
- Reduction in Circulating Microplastics in Humans Following Gastrointestinal Sequestration by Chitosan: A Pilot Controlled Study.Journal of xenobiotics · 2026Article
- Micro- and Nanoplastics as Disruptors of Digestive and Hepatopancreatic Homeostasis: Insights into the Plastic-Gut-Liver Axis.International journal of molecular sciences · 2026Review
- Microplastics enhance the risk of cross-genus dissemination of carbapenemase resistance plasmids in ICU patients.Frontiers in cellular and infection microbiology · 2026Article
- From environment to organs: individual and combined effects of MPs and PFAS on urinary system health.Frontiers in physiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of microplastics (MPs) is a possible health risk to humans. The present study aims to analyze the presence of MPs in intravenous (IV) infusions and compare MP concentrations from multiple brands. The IV solutions of 29 medical devices (IV-MDs) from seven brands commercialized in Ecuador, Spain, and Italy have been selected under specific consideration to carry out the study. The detection of MPs has been quite obvious in almost all of the samples from brands in the mentioned countries. MP concentrations ranged from 9 to 20 MPs/L in glass containers to 166-299 MPs/L in plastic bags, with the majority of fragments (63%) on fibres (37%) and more than 60% of particles less than 100 µm. Nine different types of MPs were identified in this study. High clinical risk was indicated by markings with >200 MPs/L. Nevertheless, the medium polymeric danger index (PHI) was 1.7. According to these outcomes, IV infusion is a direct exposure to MPs that may have harmful medical repercussions. It is imperative that MPs' limitations be included in pharmacopoeic monographs and in vivo toxicological and epidemiological studies. The present study aims to analyze the presence of MPs in IV-MDs and compare MP concentrations from multiple IV-MD brands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.